Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets
Authors:
- 18 March 2025
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 269, 108844
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2021YFF1000601)
- National Natural Science Foundation of China (32372826)
- Huazhong Agricultural University
This publication has 147 references indexed in Scilit:
- Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trialHepatology, 2022
- FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP‐activated protein kinase–Caspase 6 signal axisHepatology, 2022
- Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in MiceHepatology, 2021
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?Hepatology, 2015
- Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stressDiabetologia, 2014
- Low‐molecular‐weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down‐regulation of Delta‐like1Hepatology, 2014
- FGF Receptors: Cancer Biology and TherapeuticsMedicinal Research Reviews, 2013
- Endocrine fibroblast growth factors as regulators of metabolic homeostasisBioFactors, 2009
- Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via β-catenin activationHepatology, 2007